Condition
Relapsing-Remitting
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results80% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (1)
P 4 (2)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04966338Phase 3Completed
Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
NCT01791244Phase 4Completed
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
NCT01578330Phase 4Completed
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
NCT01905527Terminated
Adherence Trial With MS LifeLines ® Services
NCT00893217Phase 2Completed
BEYOND Pilot Study
Showing all 5 trials